Ionis Pharmaceuticals is participating in major medical conferences in 2026, according to outlet materials describing its presentations. The company presents at the Endocrine Society’s annual meeting (ENDO 2026), with a listed conference item for a slideshow presentation. Ionis also presents at the National Lipid Association (NLA) 2026 Scientific Sessions, again described through a slideshow format. Across the sources provided, the common point is that Ionis Pharmaceuticals is giving conference presentations at both events. The supplied text does not include specific study results, drug names, trial phases, or detailed findings from the presentations. It also does not provide timelines for when the presentations occur beyond the meeting labels, nor does it quantify any outcomes such as efficacy, safety, or regulatory progress. Overall, the information available from the provided sources is limited to confirmation of participation and presentation materials at ENDO 2026 and NLA 2026, without additional substantive clinical or commercial detail.